The fda-approved drug cobicistat synergizes with remdesivir to inhibit sars-cov-2 replication in vitro and decreases viral titers and disease progression in syrian hamsters

HIGHLIGHTS

• who: Iart Luca Shytaj et al. from the University of Bristol, Explore Bristol Research Department of Infectious Diseases, Integrative Virology, Heidelberg University, Heidelberg, Germany have published the research: The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters, in the Journal: (JOURNAL) of 14/Dec/2021
• what: Beyond its direct activity as an antiviral the authors show that cobicistat can enhance the effect of remdesivir which was one of the first drugs proposed for treatment of SARS-CoV-2 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.